Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01164813 | Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's Under Fasting Conditions | PHASE1 | COMPLETED | 44 | — | — | Mar 1, 2006 | Mar 1, 2006 | Jul 19, 2010 | 1 | India |
| NCT01164826 | Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's Under Fed Conditions | PHASE1 | COMPLETED | 30 | — | — | Mar 1, 2006 | Mar 1, 2006 | Jul 19, 2010 | 1 | India |
| Arm | Type | Description |
|---|---|---|
| Nabumetone | EXPERIMENTAL | Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited |
| Relafen | ACTIVE_COMPARATOR | Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC. |
| Name | Type | Description |
|---|---|---|
| Nabumetone | DRUG | Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited |
| Relafen | DRUG | Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC. |
Inclusion Criteria: Subjects must fulfill all of the following criteria to be considered for inclusion into this study: * Subjects who will provide written informed consent * Subjects must be healthy human beings within 18-45 years of age (inclusive) weighing at least 50 kg. * Having a Body Mass I...